Novel vasocontractile role of the P2Y14receptor: characterization of its signalling in porcine isolated pancreatic arteries by Alsaqati, Mouhamed et al.
 Novel vasocontractile role of the P2Y14 receptor: characterisation of its signalling in 
porcine isolated pancreatic arteries 
 
M. Alsaqati, M. L. Latif, S. L. F. Chan, V. Ralevic*    
 
 
 
 
Author for correspondence:  
Dr Vera Ralevic, 
School of Biomedical Sciences,  
University of Nottingham,  
Nottingham,  
NG7 2UH,  
United Kingdom. 
Tel: +44 (0)115 823 30183 
Fax: +44 (0)115 823 0142 
e-mail: vera.ralevic@nottingham.ac.uk 
 
Running title: Novel vasocontractile role of P2Y14 receptor  
  
 Background and purpose: The P2Y14 receptor is the newest member of the P2Y receptor 
family; it is Gi/o protein-coupled and is activated by UDP and selectively by UDP-glucose and 
MRS2690 (7-10 fold more potent than UDP-glucose). This study investigated whether the 
P2Y14 receptor is functionally expressed in porcine isolated pancreatic arteries.  
Experimental approach: Pancreatic arteries were prepared for isometric tension recording 
and UDP-glucose, UDP and MRS2690 applied cumulatively after preconstriction with 
U46619, a thromboxane A2 mimetic. Levels of phosphorylated MLC2 were assessed with 
Western blotting. Levels of cAMP were assessed using a competitive enzyme immunoassay 
kit. 
Key results: Concentration-dependent contraction with a rank order of potency of MRS2690 
(10-fold) > UDP-glucose ≥ UDP was observed; contraction was reduced by PPTN, a selective 
antagonist of P2Y14 receptor, which did not affect the response to UTP. Contraction to UDP-
glucose was not affected by MRS2578, a P2Y6 receptor selective antagonist. In the presence 
of U46619 and forskolin, which increases cAMP levels, contraction to UDP-glucose was 
enhanced. In addition, UDP-glucose and MRS2690 inhibited forskolin-stimulated cAMP 
levels. Removal of the endothelium and inhibition of endothelium-derived contractile agents 
(thromboxane A2, prostaglandin F2α and endothelin-1) inhibited contractions. Y-27632, 
nifedipine and thapsigargin also reduced contraction to the agonists. UDP-glucose and 
MRS2690 increased MLC2 phosphorylation, which was blocked by PPTN.  
Conclusions and implications: These data identify a novel vasocontractile role of P2Y14 
receptors in porcine pancreatic arteries. P2Y14-mediated contraction involves cAMP-
dependent mechanisms, an elevation of Ca2+ levels, activation of RhoA/ROCK signalling, and 
MLC2 in porcine pancreatic arteries. It also involves a release of thromboxane A2, 
prostaglandin F2α and endothelin-1.  
 Keywords: UDP-glucose, UDP, MRS2690, P2Y14 receptor, vasoconstriction, endothelium. 
Abbreviations: ATP, Adenosine-5'-triphosphate; HEK, human embryonic kidney; cAMP, 3'-
5'-cyclic adenosine monophosphate; DAG, diacylglycerol; IP3, inositol 1,4,5-triphosphate 
MLC2, myosin light chain 2; NDGA, nordihydroguiaretic acid; PBS, phosphate-buffered 
saline; PGF2α, prostaglandin F2α; PKC, protein kinase C; PPADS, pyridoxalphosphate-6-
azophenyl-2′,4′-disulphonate); PPTN, 4-(4-(Piperidin-4-yl)phenyl)-7-(4-
(trifluoromethyl)phenyl)-2-naphthoic acid; RhoA, ras homolog gene family member A; 
ROCK, Rho-associated protein kinase; SNP,  sodium nitroprusside; UDP, uridine diphosphate; 
UDP-glucose, uridine diphosphate glucose; UTP, uridine-5'-triphosphate. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Introduction 
 
P2Y Receptors are members of the superfamily of G-protein coupled receptors (GPCRs); they 
are responsive to purine and pyrimidine nucleotides and nucleotide sugars (ADP, ATP, UTP, 
UDP and UDP-glucose). Eight mammalian subtypes of P2Y receptors have been identified: 
P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14 receptors (Abbracchio et al., 2006). 
The P2Y14 receptor was the most recently identified (Chambers et al., 2000). In contrast to 
other P2Y receptors, P2Y14 receptors are activated by nucleotide sugars such as UDP-glucose, 
in addition to UDP-galactose and UDP-glucuronic acid which are less potent than UDP-
glucose (Abbracchio et al., 2003; Fricks et al., 2008; Harden et al., 2010). They are also 
activated by UDP and MRS2690 (2-thiouridine-5′-diphosphoglucose), which is more selective 
at P2Y14 receptors and 7-10 fold more potent than UDP-glucose (Carter et al., 2009; Jacobson 
et al., 2009; Gao et al., 2010). The P2Y14 receptor is involved in Gi-protein-mediated 
signalling, leading to the inhibition of adenylyl cyclase activity and, accordingly, is pertussis 
toxin-sensitive (Jacobson et al., 2009). Gi-protein-derived Gβγ-dimers can initiate 
phospholipase Cβ (PLCβ) signalling pathways, which lead to the stimulation of diacylglycerol 
(DAG) and inositol 1,4,5-triphosphate (IP3) and subsequent activation of RhoA/ROCK 
signalling, protein kinase C (PKC) and myosin light chain (MLC) kinase, besides elevation of 
the intracellular calcium level (Amano et al., 1996; Hartshorne & Gorecka, 2011; Sesma et al., 
2012).  
 
 Pyridoxalphosphate-6-azophenyl-2′,4′-disulphonate (PPADS) and suramin are non-selective 
antagonists at most of the P2Y receptors, but some P2Y receptors are insensitive to these 
antagonists (Chootip et al., 2005). There is currently no report of antagonist sensitivity of P2Y14 
 receptors for suramin and PPADS. Recently, a novel antagonist at P2Y14 receptors was 
identified; this antagonist, named 4-(4-(piperidin-4-yl)phenyl)-7-(4-(trifluoromethyl)phenyl)-
2-naphthoic acid (PPTN)  (Barrett et al., 2013), was characterised in HEK cells through its 
ability to inhibit UDP-glucose-stimulated Ca2+ mobilization (Robichaud et al., 2011). In 
addition, it showed good affinity for the P2Y14 receptor (Ki = 1.9 nM in a chimpanzee P2Y14 
binding assay) (Robichaud et al., 2011). When it was studied  in human C6 glioma cells, PPTN 
showed selectivity for P2Y14 receptors with a KB of 434 pM, with no agonist or antagonist 
affinity at P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12 or P2Y13 receptors (Barrett et al., 2013). 
 
P2Y14 receptor mRNA and protein have a varied expression in the body; they have been found 
in the spleen, placenta, lung, heart, adipose tissue, gastrointestinal smooth muscle,  endothelial 
cells, and immune cells (Chambers et al., 2000; Scrivens & Dickenson, 2005; Umapathy et al., 
2010). Relatively little is known, however, about the functional expression of the P2Y14 
receptor; best characterised is its role in regulation of the immune system, as a number of 
studies have described an involvement of P2Y14 receptors in modulation of the function of 
human neutrophils and T-lymphocytes, and in secretion of the pro-inflammatory cytokine IL-
8 in airway epithelial cells (Scrivens & Dickenson, 2005, 2006; Jacobson et al., 2009). UDP-
glucose can be released in a constitutive manner, and during shear stress, to act as an 
extracellular signalling molecule (Lazarowski et al., 2003); its release from multiple cell types 
suggests potentially broad role(s) of the P2Y14 receptor.  
 
Although the exact mechanisms remain to be established, an increase in pancreatic endocrine 
cell activity during hormone secretion corresponds with an increase in blood flow, to meet 
metabolic demand. Thus, alterations in blood flow can influence pancreatic function. The role 
of exogenous purine and pyrimidine di- and triphosphate nucleotides in controlling the 
 functions of endocrine and exocrine components of the pancreas are well described (Novak, 
2008; Burnstock & Novak, 2012). Within the pancreatic vasculature, P2X receptors were 
suggested to mediate vasoconstriction, and P2Y receptors vasodilatation, in response to ATP 
(Hillaire-Buys et al., 1991). P2X1, P2Y2, P2Y4 and P2Y6 receptors, with different sensitivities 
to ATP, UDP and UTP, mediate vasoconstriction in a number of blood vessels (Ralevic and 
Burnstock, 1998), and there is some evidence for a vasocontractile function of the P2Y12 
receptor (Wihlborg et al., 2004; Högberg et al., 2010). In the current study, we describe the 
pharmacological characterisation of P2Y14 receptor-mediated contractile responses of porcine 
isolated pancreatic artery preparations. A preliminary account of some of these data has 
previously been presented to the British Pharmacological Society (Alsaqati et al., 2010). 
 
Materials and methods 
Tissue Preparation 
Pancreases from pigs (either sex, age less than 6 mo, wt ~50 kg) was obtained on ice from a 
local abattoir (G Wood & Sons Ltd, Mansfield). A crude dissection was conducted to isolate 
the pancreatic arteries (greater pancreatic artery) which were located in the body of the 
pancreas. The vessels were dissected out and placed in Krebs’-Henseleit buffer containing 2% 
(w/v) Ficoll (type 70) and refrigerated overnight at 4ºC. The next day, fine dissection was 
performed, and the arteries cut into rings of 0.5 cm in length and suspended in Krebs’-Henseleit 
buffer (gassed, 95% O2, 5% CO2).  
The endothelium of some arteries was removed by gently rubbing their innermost surface with 
forceps before attaching it to the setup (Rayment et al., 2007a). Successful removal of 
endothelium was tested using substance P (10 nM). Endothelium-denuded arteries relaxed in 
response to substance P to less than 10% of the U46619 (11α,9α-epoxymethano-PGH2) induced 
 contraction, while in endothelium-intact arteries the relaxation to substance P was 36% ± 8 
(n=7, data not shown). 
 
Responses in the porcine isolated pancreatic artery 
 
Arterial rings were mounted onto wires in tissue baths (20 ml) containing warm (37°C), 
oxygenated Krebs’-Henseleit solution and were connected via isometric force transducers 
(ADInstruments, Sydney, Australia), to a PC running the computer program LabChart 
(ADInstruments, Sydney, Australia). Rings were put under tension (15 g) and allowed to 
equilibrate for 60 min before assessing viability with two challenges of 75 mM potassium 
chloride (KCl). The tissues were then allowed to equilibrate for 60 min, after which U46619 
(10 - 100 nM), a thromboxane A2 mimetic, was used to contract the tissues to between 40-80% 
of the second KCl response. This ensured that if there was a vasodilator component to the 
response, for example due to activation of multiple P2 receptor subtypes, this could be detected. 
Once an appropriate level of U46619 response had been achieved, cumulative addition of UDP-
glucose, UDP or MRS2690 were applied. Antagonists or inhibitors were applied 10 min prior 
to the addition of U46619, allowing incubation with the tissues for a minimum of 30 min prior 
to the application of agonists. Desensitisation of the contraction to UDP-glucose was generated 
by exposing the arteries to UDP or UDP-glucose 10 min prior the addition of U46619. An 
exception to preconstriction with U46619, were experiments with L-655,240 (1-[(4-
Chlorophenyl)methyl]-5-fluoro--α,α,3-trimethyl-1H-indole-2-propanoic acid), in which 
arteries were preconstricted with endothelin-1. In experiments using dimethyl sulfoxide 
(DMSO) as the solvent (see reagents and drugs section), DMSO was added to the arteries 
(vehicle control). 
 
 Effect of forskolin on subsequent UDP-glucose or UTP responses 
Tissues were exposed to U46619 (10 - 100 nM) and relaxed with forskolin (1 µM), involving 
elevation of cAMP, back to the baseline; cumulative concentration-response curves were then 
constructed for UDP-glucose (1 µM – 1 mM) or UTP (10 µM – 1 mM). Responses to UDP-
glucose or UTP obtained under these conditions were compared to control responses in which 
drugs were added at basal tone without exposing to either U46619 or forskolin. The tissue was 
allowed to recover for 20 min before a concentration-response curve to UDP-glucose or UTP 
was constructed. 
Western blotting 
Segments of porcine pancreatic arteries were set up in the organ baths and tensioned to 15 g, 
then left for approximately 60 min to reach a new baseline of resting tension. Tissues were 
incubated with 100 µM UDP-glucose for 30, 60, 120, 180, 240 and 300 s. In addition, in other 
experiments, the tissues were incubated with UDP-glucose (100 µM) or MRS2690 (10 µM) 
for 30 s in the presence or absence of PPTN. Segments were quickly removed from the organ 
baths and immediately frozen on dry ice. Control tissues were not exposed to any compound 
(basal conditions). Segments were then homogenised in lysis buffer (20 mM Tris, 1 mM 
EGTA, 0.1% (v/v) Triton X100, 1 mM NaF, 10 mM beta glycerophosphate, pH 7.6), containing 
protease inhibitor cocktail tablets, EDTA free. Samples with solubilisation buffer 6×SB: (24% 
(w/v) sodium dodecyl sulphate, 30% (v/v) glycerol, 5% (v/v) beta mercaptoethanol, 2.5% (v/v) 
bromophenol blue, 1.5M Tris HCl, pH 6.8 ) were heated at 95°C for 5 min. Subsequently, 
electrophoresis was carried out on 4-20% Tri-Glycine (PAGE) Gold Precast Gels (Bio-Rad, 
Hercules, CA, U.S.A.), 15 µg protein per lane. Samples were transferred to nitrocellulose 
membranes. Next, blots were incubated in blocking solution (5% (w/v) powdered milk in Tris-
buffered saline containing 0.1% (v/v) Tween 20) for 60 min, at room temperature. Blots were 
 incubated overnight at 4°C with primary antibody against phosphorylated myosin light chain 
kinase 2 (MLC2, 1:500) or total (MLC2, 1:1000) diluted in blocking solution. After washing 
in Tris buffered saline containing 0.1% (v/v) Tween 20, the blots were incubated with an 
appropriate IRDye®-conjugated secondary antibody (LI-COR). Proteins were visualised using 
the Licor/Odyssey infrared imaging system (Biosciences, Biotechnology). Bands were 
analyzed by densitometry using the Odyssey application software and expressed as 
phosphorylated MLC2 normalised to total MLC2. For investigating the existence of P2Y14 
receptor in pancreatic arteries, untreated samples were homogenised and examined as 
explained above. 
cAMP measurement in porcine pancreatic arteries 
 
Pancreatic artery rings were stimulated with 75 mM KCl followed by U46619 (10 nM) and 
forskolin (1 µM), and then the arteries were challenged for 3 min with UDP-glucose (1 mM), 
MRS2690 (10 µM), UTP (1 mM) or distilled water (control group). Pancreatic rings were 
collected and immediately frozen on dry ice and then stored in vials at -80 C until their study. 
The tissues were homogenised in 5% (w/v) trichloroacetic acid (TCA) in water with a 
borosilicate glass, homogeniser, and then centrifuged for 10 min at 1500 g. TCA was extracted 
from the supernatant samples using water-saturated ether, and evaporated for 5 min to remove 
the residual ether from the aqueous fractions. Samples were diluted (1:2) in ether-extracted 5% 
(w/v) TCA. cAMP concentration was measured using a competitive enzyme immunoassay kit 
(Cayman Chemical Co., Ann Arbor, MI). The working range of the cAMP assay was 0.1–1000 
pmol/ml. cAMP concentration was expressed as a percentage of forskolin-induced [cAMP] 
elevation.  
 
 
 
 Reagents and Drugs 
Krebs’-Henseleit buffer was composed of the following (mM); NaCl 118, KCl 4.8, CaCl2.H2O 
1.3, NaHCO3 25.0, KH2PO4 1.2, MgSO4.7H2O 1.2 and glucose 11.1. Suramin, NDGA, 
nifedipine, thapsigargin, UTP, U46619, sodium nitroprusside (SNP), zafirlukast, BQ788 (N-
cis-2,6-dimethylpiperidinocarbonyl-L-gmethylleucyl-D-1-methoxycarboyl-D-norleucine), 
UDP-glucose and UDP were purchased from Sigma (Poole, Dorset, UK), while DUP 697, 
MRS2578 (N,N″-1,4-butanediyl bis(N′-[3-isothiocynatophenyl)] thiourea), PPADS and 
substance P, MRS2690, L-655,240, endothelin-1, BQ123 (cyc(DTrp-DAsp-Pro-D-Val-Leu)), 
Y-27632 (trans-4-[(1R)-1-aminoethyl]-N-4-pyridinyl-cyclohexane carboxamide) and 
forskolin were from Tocris Biosciences Ltd. (Bristol, UK). PPTN, a selective high affinity 
antagonist of P2Y14 receptor, was kindly gifted from Merck Frosst Centre for Therapeutic 
Research. Primary antibodies for Western blotting were purchased from Cell Signalling 
Technology for phosphorylated MLC2 antibody, (cat no. 3674S) and total MLC2 antibody, 
(cat no. 3672). Cyclic AMP EIA kit (cat No. 581001) was purchased from Cayman Chemical 
Company, (Ann Arbor, MI). U46619 was dissolved in ethanol at 10 mM stock concentration. 
DUP 697, PPTN, BQ788, MRS2578, L-655,240, nifedipine, thapsigargin, zafirlukast and 
forskolin were dissolved in DMSO. All other drugs were dissolved in distilled water. All 
reagents and drugs nomenclature conformed to BJP's Guide to Receptors and Channels 
(Alexander et al., 2011). 
Data Analysis 
Data were expressed as log concentration-response plots. The contraction to all agonists was 
expressed in g, and measured from the stabilised U46619 response. Values for all figures refer 
to mean ± S.E.M with 95% confidence. Results were compared by two-way ANOVA or 
 Student’s unpaired t-test (Prism, GraphPad, San Diego, CA, USA). Differences were 
considered to be significant when the P value was < 0.05. N expresses the number of animals. 
 
Results 
Effect of UDP-glucose, UDP and MRS2690 in porcine isolated pancreatic arteries 
To investigate the possible functional expression of P2Y14 receptors and their role in porcine 
pancreatic arteries, agonists for this receptor were applied as cumulative concentrations. 
MRS2690, a selective P2Y14 receptor agonist (0.1 µM to 30 µM), UDP-glucose (1 µM to 1 
mM) and UDP (1 µM to 1 mM) were added after preconstriction with U46619. All of the 
agonists induced a concentration-dependent contraction with a rank order of potency of 
MRS2690 > UDP-glucose ≥ UDP.  MRS2690 was significantly more potent, by approximately 
10-fold, than UDP-glucose (P < 0.01, two-way ANOVA, Figure 1A), while UDP-glucose and 
UDP responses were equipotent (Figure 1A). Both UDP-glucose and UDP (P2Y14 receptor 
agonists) separately induced significant attenuation of the contraction to UDP-glucose; for 
instance, the response to 100 µM UDP-glucose was decreased by 55 ± 7% in the presence of 
100 µM UDP-glucose, and by 53 ± 7% in the presence of 100 µM UDP (P < 0.001, n=10-13, 
Figure 1B). 
 
Effect of PPADS and suramin on responses to UDP-glucose, UDP and MRS2690 in 
porcine isolated pancreatic arteries 
Responses to UDP-glucose, UDP and MRS2690 were characterised using the non-selective P2 
receptor antagonists PPADS (10 µM) and suramin (100 µM) (Rayment et al., 2007b). Both 
PPADS and suramin significantly enhanced the contractions evoked by UDP-glucose and UDP 
(Figure 2A, 2B). The contraction to 100 µM UDP-glucose was enhanced by 121 ± 38% (P < 
 0.001, n=7) and by 100 ± 23% (P < 0.001, n=8) in the presence of PPADS and suramin 
respectively (Figure 2A). The contraction to 1 mM UDP was enhanced by 180 ± 46% (P < 
0.001, n=8), and by 154 ± 30% (P < 0.001, n=8) in the presence of PPADS and suramin 
respectively (Figure 2B). Suramin and PPADS failed to alter the contraction to MRS2690 
(Figure 2C). In contrast, suramin and PPADS blocked the contraction to UTP, a P2Y2 and P2Y4 
receptors agonist (von Kügelgen, 2006) (unpublished observations). UDP is a ligand at P2Y6 
receptors as well as P2Y14 receptors. Therefore, the effect of UDP was examined in the 
presence of MRS2578 (10 µM), a P2Y6 receptor selective antagonist (Mamedova et al., 2004). 
The contraction evoked by UDP was unaffected at lower concentrations but was augmented at 
higher concentrations of UDP (supplementary information), while MRS2578 did not alter the 
responses to UDP-glucose or MRS2690 (supplementary information).  
 
Effect of PPTN, a selective high affinity antagonist of P2Y14 receptor, on responses to 
UDP-glucose and MRS2690 in porcine isolated pancreatic arteries 
The responses to UDP-glucose and MRS2690 were examined in the presence of PPTN (1 µM), 
a selective high affinity antagonist of P2Y14 receptor (Robichaud et al., 2011; Barrett et al., 
2013). This compound significantly reduced the contraction evoked by UDP-glucose at basal 
tone (Supplementary information) and that by UDP-glucose and MRS2690 at raised tone 
(Figure 3A, 3B). PPTN inhibited the contraction to 100 µM UDP-glucose and to 10 µM 
MRS2690 by 55 ± 10% (P < 0.05, n=7) and by 46 ± 9% (P < 0.01, n=9) respectively (Figure 
3A, 3B). The contraction to UTP was not altered in the presence of PPTN (Figure 3C). Typical 
traces, showing the effect of MRS2690 in the absence and in the presence of PPTN, are shown 
in Figure 3D. 
 
 Effect of endothelium removal on responses to UDP-glucose, UDP and MRS2690 in 
porcine isolated pancreatic arteries 
The responses of UDP-glucose, UDP and MRS2690 were studied after the endothelium had 
been removed. The contractions induced by UDP-glucose, UDP and MRS2690 were 
significantly attenuated in the endothelium-denuded arteries (Figure 4). Removal of 
endothelium reduced the contractions to 1 mM UDP-glucose by 50 ± 7% (P < 0.001, n=12), 
that to 1 mM UDP by 61±11% (P < 0.001, n=15) and that to 30 µM MRS2690 by 41 ± 5% (P 
< 0.01, n=5) (Figure 4). 
 
Effect of DUP 697 on responses to UDP-glucose, UDP and MRS2690 in porcine isolated 
pancreatic arteries 
Because the contractions to P2Y14 receptor agonists were mainly endothelium-dependent, these 
were studied in the presence of DUP 697, a cyclooxygenase-2 (COX-2) inhibitor, since COX-
2 facilitates the release of agents which are responsible for endothelium-dependent contraction. 
DUP 697 (3 µM) diminished the responses to UDP-glucose, UDP and MRS2690 to a similar 
extent as removal of the endothelium (Figure 5), while DUP 697 did not alter the contraction 
to U46619 (the preconstriction agent) or the contraction to ATP (data not shown). DUP 697 
reduced the contraction to 1 mM UDP-glucose by 34 ± 10% (P < 0.001, n=11), that to 1 mM 
UDP by 38 ± 7.5% (P < 0.001, n=15) and that to 30 µM MRS2690 by 22.5 ± 13% (P < 0.01, 
n=4), (Figure 5).  
 
 
 
 The role of endothelium-derived contracting factors in the response to UDP-glucose in 
porcine isolated pancreatic arteries 
The following experiments were carried out using mainly UDP-glucose or UDP due to the cost 
considerations involved with use of MRS2690. The possible involvement of thromboxane A2, 
leukotrienes, endothelin-1 and PGF2α, which can be released from endothelial cells (Mombouli 
& Vanhoutte, 1993; Kurahashi et al., 2003; Wong et al., 2009), in endothelially-mediated 
contraction to UDP-glucose was investigated. The contraction to UDP-glucose was not altered 
in the presence of nordihydroguaiaretic acid (NDGA) (10 µM), a lipoxygenase inhibitor 
(Figure 6A) or zafirlukast (10 µM), a leukotriene receptor inhibitor (Figure 6B). The 
contraction to UDP-glucose was reduced in the presence of BQ123 (1 µM), a selective ETA 
receptor antagonist; the response to 100 µM UDP-glucose was attenuated by 10 ± 3% (P < 
0.05, n=14) in the presence of BQ123 (Figure 6C), which was only effective with intact 
endothelium (Supplementary information). The contraction to UDP-glucose was unaltered in 
the presence of BQ788 (1 µM), a selective ETB receptor antagonist (Supplementary 
information). In addition, UDP-glucose induced-contraction was reduced in the presence of L-
655,240 (1 µM), a selective thromboxane A2/prostaglandin endoperoxide receptor antagonist. 
The response to 100 µM UDP-glucose was inhibited by 38 ± 5% (P < 0.001, n=9) in the 
presence of L-655,240 (Figure 6D). These data indicate that UDP-glucose mediated-
contraction occurs mainly via thromboxane and prostaglandins, with a lesser involvement of 
endothelin-1. 
 
Effect of inhibition of calcium release and calcium entry on the response to UDP-glucose 
and UDP in porcine isolated pancreatic arteries 
Binding of agonist to the recombinant P2Y14 receptor leads to increase Ca
2+ flux in some cells 
(Skelton et al., 2003; Gao et al., 2010). To test this in porcine pancreatic arteries, responses to 
 UDP-glucose and UDP were examined in the presence and absence of nifedipine (1 µM), an 
L-type voltage-gated calcium channel blocker, and thapsigargin (100 nM), a potent inhibitor 
of sarco-endoplasmic reticulum Ca2+-ATPases which leads to depletion of intracellular 
calcium. Both of these inhibitors reduced the contraction evoked by 100 µM UDP-glucose, by 
39 ± 5% (P < 0.001, n=15) in the presence of nifedipine, and by 25 ± 8% (P < 0.05, n=12-15) 
in the presence of thapsigargin (Figure 7A, 7B). Responses to 100 µM UDP were inhibited by 
53 ± 2% (P < 0.001, n=9) in the presence of nifedipine, and by 36 ± 6% (P < 0.001, n=9) in the 
presence of thapsigargin (data not shown). Typical traces showing the effect of UDP-glucose 
in the absence and in the presence of nifedipine are shown in Figure 7C. 
 
Effect of inhibition of the Rho-kinase pathway on the responses to UDP-glucose, UDP and 
MRS2690 in porcine isolated pancreatic arteries 
Following the activation of P2Y14 receptors, MLC may be phosphorylated because of upstream 
stimulatory RhoA/ROCK signalling (Amano et al., 1996; Hartshorne & Gorecka, 2011). To 
test the possible involvement of this pathway, experiments were conducted to study the 
contractions to UDP-glucose, UDP and MRS2690 in the presence of Y-27632 (5 µM), a 
selective inhibitor of the Rho-associated protein kinase p160ROCK. Y-27632 significantly 
inhibited the contraction evoked by UDP (Figure 8A), MRS2690 (Figure 8B) and UDP-glucose 
(data not shown). For instance, the response to 300 µM UDP was reduced by 50± 4% (P < 
0.001, n=15, Figure 8A), that to 30 µM MRS2690 by 50 ± 15% (P < 0.001, n=9, Figure 8B) 
and that to 1 mM UDP-glucose by 52 ± 8% (P < 0.001, n=9, data not shown). The response to 
UDP-glucose was associated with an increase in the level of MLC2 phosphorylation, after 30–
60 s of treatment with 100 µM UDP-glucose, and returned to the basal level of phosphorylated 
MLC2 from 120-300s (Figure 8C), which suggested an involvement of MLC2 activation in the 
response to UDP-glucose P2Y14 receptor signalling pathway. The ability of UDP-glucose (100 
 µM) or MRS2690 (10 µM) to elevate the MLC2 phosphorylation (after 30 s of treatment) was 
abolished in the presence of PPTN (1 µM), which shows that the ability of UDP-glucose or 
MRS2690 to elevate MLC2 phosphorylation in porcine pancreatic arteries is mediated by 
P2Y14 receptors (Figure 9). 
 
 
Effect of pre-constriction with U46619, and relaxation with forskolin, on the response to 
UDP-glucose in porcine isolated pancreatic arteries 
Agonist-promoted activation of Gi and subsequent inhibition of adenylyl cyclase is one of the 
signalling responses of P2Y14 receptors. Therefore, the response to UDP-glucose was tested 
after exposure to U46619 and subsequent relaxation by forskolin (back to the baseline), 
involving elevation of intracellular cyclic AMP. UDP-glucose induced a greater contraction 
compared with the control, in which UDP-glucose was applied at basal tone without the tissues 
being exposed to U46619 or forskolin (Figure 10). The contraction to 100 µM UDP-glucose 
was enhanced by 930 ± 108% (P < 0.001, n=11) after the exposure to U46619 and forskolin 
(Figure 10A). In contrast, when responses to UTP, an agonist at P2Y2 and P2Y4 receptors (Gq 
protein coupled receptors) were investigated in vessels exposed to U46619 and forskolin, there 
was no change in the contractions (Figure 10B). In addition, the response to UDP-glucose was 
not altered after contraction with U46619 and relaxation with SNP (100 µM), which elevates 
intracellular cyclic GMP (Roberts et al., 1999). Typical traces showing the effect of UDP-
glucose on basal tone and after the tissues had been contracted by U46619 and then relaxed 
with forskolin are shown in Figure 10C. 
 
Effect of UDP-glucose and MRS2690 on the cAMP level in porcine isolated pancreatic 
arteries 
 On the basis that cAMP is involved in the contraction to P2Y14 receptor agonists, we measured 
the cellular levels of this second messenger in pancreatic artery rings. We investigated the 
effects of UDP-glucose, MRS2690 and UTP (as a control, since it is coupled to Gq protein) on 
cAMP level in the presence of U46619 + forskolin (to mimic the raised tone condition of the 
pharmacology experiments). UDP-glucose (1 mM) and MRS2690 (10 µM) induced a 
significant decrease in cAMP level in relative to the control (*P < 0.05, n=4), while UTP had 
no significant effect on cAMP levels (Figure 11). 
 
Discussion 
The current study presents evidence for the functional expression of contractile P2Y14 
receptors, sensitive to the endogenous nucleotides UDP-glucose and UDP in arteries of pig 
pancreas. Evidence from the contractile studies and the cAMP immunoassay is consistent with 
the ability of this receptor to inhibit adenylyl cyclase, while immunoblotting indicates the 
downstream involvement of MLC2. The contractile response was mediated largely by the 
endothelium with an involvement of endothelin, thromboxane A2 and PGF2α. 
 
Contractile studies showed that contractions to UDP-glucose and UDP were almost equipotent, 
whereas the contraction to MRS2690, a selective P2Y14 receptor agonist, was approximately 
10-fold more potent than that of UDP-glucose at the P2Y14 receptor (Figure 1A). This is 
consistent with previous reports which suggest a 7-10 fold greater potency of MRS2690 over 
UDP-glucose (Jacobson et al., 2009;  Gao et al., 2010). MRS2690 activity was observed at ≤ 
10 µM; at 10 µM MRS2690 has been reported to be inactive at P2Y2 receptors (Ko et al., 
2009). 
 PPTN is a non-nucleotide, high affinity competitive antagonist at P2Y14 receptors. It was 
assessed in HEK cells using a calcium mobilization assay and it inhibited UDP-glucose 
mediated signalling, and showed no effect on other P2Y receptors at concentrations up to 10 
µM (Robichaud et al., 2011; Barrett et al., 2013). The responses to the P2Y14 receptor agonists 
were examined in the presence of this antagonist. PPTN blocked the contractions induced by 
UDP-glucose and MRS2690 which confirms the involvement of P2Y14 receptors in our arteries 
(Figure 3A, 3B).  
The responses to the P2Y14 receptor agonists were examined in the presence of the non-
selective P2 receptor antagonists, suramin and PPADS. The non-selective antagonists induced 
a small increase in the contractions to UDP and UDP-glucose (Figure 2A, 2B). However, they 
failed to change the response to MRS2690 (Figure 2C). The lack of effect of suramin and 
PPADS appears to rule out an involvement of P2Y2 and/or P2Y4 receptors, since we have 
shown that they blocked the responses to UTP in porcine pancreatic arteries (unpublished 
observations) and other tissues (Rayment et al., 2007b).  It is unclear why these antagonists 
enhanced the effects of P2Y14 receptor agonists. However, it is clear that suramin and PPADS 
had different effect on UTP responses versus responses of MRS2690 and UDP-glucose 
indicating actions at different receptors. 
Contractile responses to UDP-glucose, UDP and MRS2690 were significantly inhibited after 
the endothelium was removed (Figure 4), which indicated that the main expression of P2Y14 
receptor may be on the endothelial layer of porcine pancreatic arteries. Similarly, the P2Y14 
receptor has been reported to be expressed in endothelial cells of porcine coronary artery, 
human lung microvascular endothelial cells, and pulmonary artery vasa vasorum endothelial 
cells (Umapathy et al., 2010; Abbas et al., 2011; Lyubchenko et al., 2011). P2Y14 receptor 
expression was barely detectable in mouse thoracic aorta (Kauffenstein et al., 2010); in 
 contrast, rat aortic smooth muscle cells show robust expression of the receptor, as observed in 
freshly isolated and cultured cells (Govindan et al., 2010). 
To investigate the mechanism underlying the contraction mediated by P2Y14 receptors in 
pancreatic arteries, responses to UDP-glucose, UDP and MRS2690 were examined in the 
presence of DUP 697. As seen in Figure 5, the endothelium-dependent contractions were 
attenuated in the presence of the selective COX-2 inhibitor. Endothelial cells can release 
contractile factors (EDCFs), which may include thromboxane A2, PGF2α, leukotrienes and 
endothelin-1. Thromboxane A2 and PGF2α are released from the endothelium due to the activity 
of cyclooxygenase-2 (Mombouli & Vanhoutte, 1993; Wong et al., 2009). To characterise 
EDCFs involved in the contraction to UDP-glucose, experiments were conducted to study the 
responses to UDP-glucose in the presence of zafirlukast, BQ123, BQ788 and L-655,240. Only 
BQ123 and L-655,240 were able to inhibit the contraction evoked by UDP-glucose which 
indicated an involvement of thromboxane A2, prostaglandins and endothelin-1 (Figure 6). 
These agents, after being released from the endothelium, may act on their receptors on vascular 
smooth muscle cells (Wong et al., 2009). 
The involvement of extracellular calcium influx and calcium released from sarcoplasmic 
reticulum (SR) as a part of the response to P2Y14 receptors activation has been reported (Verin 
et al., 2011). In addition, calcium-induced release of calcium from SR and influx of external 
Ca2+ in excitation-contraction in response to some activated receptors have been also reported 
(Fabiato, 1983; Li et al., 2003). In porcine pancreatic arteries, contractions to UDP-glucose 
(Figure 7A, B) and UDP (data not shown) were significantly decreased in the presence of 
nifedipine or thapsigargin, which identified an involvement of elevated intracellular calcium 
level. Collectively, our results suggest that when UDP-glucose, UDP and MRS2690 act at the 
P2Y14 receptors, which are expressed mainly on the endothelium, the intracellular Ca
2+ levels 
may be elevated; this may then activate endothelin-1 and phospholipase A2 which liberates 
 arachidonic acid, which is then converted by the activity of COX-2 to produce the contractile 
agents, thromboxane A2 and prostaglandin, which bind to receptors on vascular smooth muscle 
cells to induce contraction.  
 
A number of studies have considered the signalling mechanism underlying the functional 
response of P2Y14 receptors (Harden et al., 2010; Sesma et al., 2012). Recent reports claimed 
that UDP-glucose promotes concentration-dependent activation of RhoA in isolated human 
neutrophils (Sesma et al., 2012). This was tested in porcine pancreatic arteries when responses 
were investigated in the presence of Y-27632; this compound inhibited the contraction evoked 
by UDP-glucose, UDP and MRS2690 (Figure 8A, 8B), which showed an involvement of RhoA 
in the response to P2Y14 receptor agonists. Activation of RhoA leads to phosphorylation of 
MLC and subsequently contraction of arteries in a calcium-independent manner (Amano et al., 
1996; Hartshorne & Gorecka, 2011). Accordingly, when UDP-glucose or MRS2690 were 
incubated with the tissues, the level of phosphorylated MLC2 was elevated, but this elevation 
was abolished in the presence of PPTN, confirming that it is happening through the activation 
of P2Y14 receptors (Figure 8C, 9). 
It is well established that the P2Y14 receptor is coupled to Gi protein, leading to the inhibition 
of forskolin-stimulated adenylyl cyclase activity, and hence inhibition of the cyclic AMP level. 
Accordingly, the P2Y14 receptor is pertussis toxin-sensitive (PTX) (Jacobson et al., 2009). It is 
notoriously difficult to successfully block Gi coupled receptors with PTX in isolated blood 
vessels, as we have also found. However, in tissues which had been preconstricted with U46619 
and relaxed with forskolin (to elevate the cAMP levels), subsequent addition of UDP-glucose 
produced a significantly greater contraction compared with the controls (UDP-glucose added 
at basal tone, or UTP applied after preconstriction with U46619 and relaxation with forskolin) 
(Figure 10), consistent with an involvement of Gi coupled receptors. Other purine receptors, 
 namely P2Y1, P2Y2, P2Y4, P2Y6 receptors, are generally Gq protein-coupled. Furthermore, 
relaxation with SNP (to elevate cGMP levels) after preconstriction with U46619 had no effect 
on the contractile response to UDP-glucose (data not shown). These findings together with the 
data obtained from cAMP assay (Figure 11) indicate that the enhanced contraction to UDP-
glucose is mainly dependent on the agonist's ability to lower cyclic AMP levels.  
Reduction in pancreatic blood flow has been observed in acute and chronic pancreatitis and 
some other pancreatic diseases (Satoh et al., 2000; Nguyen et al., 2010), implicating pancreatic 
tissue perfusion as an important factor in pathogenesis of pancreatic diseases and symptoms. 
There is increasing evidence for the role of purinergic signalling in the pathophysiology of the 
pancreas (Burnstock & Novak, 2012). Drugs designed to target specific component of 
purinergic system may be of relevance to the management of pancreatitis, cystic fibrosis, 
pancreatic cancer and diabetes. 
In conclusion, this study has shown a novel vasocontractile action of UDP-glucose which 
appears to be mediated by the P2Y14 receptor in porcine isolated pancreatic arteries. P2Y14 
receptors induce contraction via an involvement of endothelin-1, thromboxane A2 and 
prostaglandins released from the endothelium. In addition, P2Y14-mediated contraction 
involves the activation of Rho kinase, and the subsequent phosphorylation of MLC2. The 
ability of P2Y14-receptor agonist to inhibit cAMP level indicates P2Y14 receptor coupling to Gi 
proteins. This study identifies a novel role for the P2Y14 receptor as a vasocontractile P2 
receptor. 
Acknowledgments 
We would like to thank Merck Frosst Centre for Therapeutic Research, for a generous gift of 
PPTN, Dr. W Cameron Black for his helpful discussion, Dr. Richard Roberts for his generous 
donation of BQ123, and Damascus University in Syria for funding the project.  
  
References 
Abbas Z, Latif L, Ralevic V, (2011). Effects of P2Y14 Receptor Agonists, UDP-glucose and 
MRS2690, on Porcine Coronary Artery Contractility 
http://www.pA2online.org/abstracts/Vol9Issue3abst051P.pdf. 
Abbracchio MP, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Miras-Portugal MT, et 
al. (2003). Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) 
adds diversity to the P2Y receptor family. Trends Pharmacol Sci24(2): 52-55. 
Abbracchio MP, Burnstock G, Boeynaems J-M, Barnard EA, Boyer JL, Kennedy C, et al. 
(2006). International Union of Pharmacology LVIII: Update on the P2Y G Protein-Coupled 
Nucleotide Receptors: From Molecular Mechanisms and Pathophysiology to Therapy. 
Pharmacol Rev 58(3): 281-341. 
Alexander, S.P.H., Mathie, A., Peters, J.A. (2011). Guide to Receptors and Channels (GRAC), 
5th edition (2011). Br. J. Pharmacol., 164(Suppl. 1), S1–S324. 
Alsaqati M, Latif LL, Chan SLF, Ralevic R, (2010). Identification of the novel P2Y14 receptor 
in porcine isolated pancreatic arteries, 
http://www.pa2online.org/abstracts/vol8issue1abst028p.pdf. 
Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, et al. (1996). Phosphorylation 
and Activation of Myosin by Rho-associated Kinase (Rho-kinase). Journal of Biological 
Chemistry271(34): 20246-20249. 
Barrett MO, Sesma JI, Ball CB, Jayasekara PS, Jacobson KA, Lazarowski ER, et al. (2013). A 
Selective High Affinity Antagonist of the P2Y14 Receptor Inhibits UDP-Glucose-Stimulated 
Chemotaxis of Human Neutrophils. Molecular pharmacology. 
Burnstock G, Novak I (2012). Purinergic signalling in the pancreas in health and disease. 
Journal of Endocrinology 213(2): 123-141. 
Carter RL, Fricks IP, Barrett MO, Burianek LE, Zhou Y, Ko H, et al. (2009). Quantification 
of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of 
the human P2Y14 receptor. Molecular pharmacology 76(6): 1341-1348. 
Chambers JK, Macdonald LE, Sarau HM, Ames RS, Freeman K, Foley JJ, et al. (2000). A G 
protein-coupled receptor for UDP-glucose. J Biol Chem 275(15): 10767-10771. 
Chootip K, Gurney AM, Kennedy C (2005). Multiple P2Y receptors couple to calcium-
dependent, chloride channels in smooth muscle cells of the rat pulmonary artery. Respir Res 
6(1): 124. 
Fabiato A (1983). Calcium-induced release of calcium from the cardiac sarcoplasmic 
reticulum. The American journal of physiology 245(1): C1-14. 
Fricks IP, Maddileti S, Carter RL, Lazarowski ER, Nicholas RA, Jacobson KA, et al. (2008). 
UDP is a competitive antagonist at the human P2Y14 receptor. J Pharmacol Exp Ther 325(2): 
588-594. 
Gao ZG, Ding Y, Jacobson KA (2010). UDP-glucose acting at P2Y14 receptors is a mediator 
of mast cell degranulation. Biochem Pharmacol 79(6): 873-879. 
 Govindan S, Taylor EJ, Taylor CW (2010). Ca(2+) signalling by P2Y receptors in cultured rat 
aortic smooth muscle cells. Br J Pharmacol 160(8): 1953-1962. 
Harden TK, Sesma JI, Fricks IP, Lazarowski ER (2010). Signalling and pharmacological 
properties of the P2Y receptor. Acta Physiol (Oxf) 199(2): 149-160. 
Hartshorne DJ, Gorecka A (2011). Biochemistry of the Contractile Proteins of Smooth Muscle. 
Comprehensive Physiology, edn: John Wiley & Sons, chapter 4, 93-120. 
Hillaire-Buys D, Chapal J, Petit P, Loubatières-Mariani M-M (1991). Dual regulation of 
pancreatic vascular tone by P2X and P2Y purinoceptor subtypes. Eur J Pharmacol 199(3): 
309-314. 
Högberg C, Svensson H, Gustafsson R, Eyjolfsson A, Erlinge D (2010). The reversible oral 
P2Y12 antagonist AZD6140 inhibits ADP-induces contractions in murine and human 
vasculature. Int J Cardiol 142(2): 187-192. 
Jacobson KA, Ivanov AA, de Castro S, Harden TK, Ko H (2009). Development of selective 
agonists and antagonists of P2Y receptors. Purinergic Signal 5(1): 75-89. 
Kauffenstein G, Drouin A, Thorin-Trescases N, Bachelard H, Robaye B, D'Orléans-Juste P, et 
al. (2010). NTPDase1 (CD39) controls nucleotide-dependent vasoconstriction in mouse. 
Cardiovasc Res 85(1): 204-213. 
Ko H, Das A, Carter RL, Fricks IP, Zhou Y, Ivanov AA, et al. (2009). Molecular recognition 
in the P2Y(14) receptor: Probing the structurally permissive terminal sugar moiety of uridine-
5'-diphosphoglucose. Bioorganic & medicinal chemistry 17(14): 5298-5311. 
Kurahashi K, Nishihashi T, Trandafir CC, Wang AM, Murakami S, Ji X (2003). Diversity of 
endothelium-derived vasocontracting factors--arachidonic acid metabolites. Acta 
pharmacologica Sinica 24(11): 1065-1069. 
Lazarowski ER, Shea DA, Boucher RC, Harden TK (2003). Release of cellular UDP-glucose 
as a potential extracellular signalling molecule. Mol Pharmacol 63(5): 1190-1197. 
Li N, Sul JY, Haydon PG (2003). A calcium-induced calcium influx factor, nitric oxide, 
modulates the refilling of calcium stores in astrocytes. The Journal of neuroscience : the official 
journal of the Society for Neuroscience 23(32): 10302-10310. 
Lyubchenko T, Woodward H, Veo KD, Burns N, Nijmeh H, Liubchenko GA, et al. (2011). 
P2Y1 and P2Y13 purinergic receptors mediate Ca
2+ signaling and proliferative responses in 
pulmonary artery vasa vasorum endothelial cells. American Journal of Physiology - Cell 
Physiology 300(2): C266-C275. 
Mamedova LK, Joshi BV, Gao ZG, von Kugelgen I, Jacobson KA (2004). Diisothiocyanate 
derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochemical 
pharmacology 67(9): 1763-1770. 
Mombouli JV, Vanhoutte PM (1993). Purinergic endothelium-dependent and -independent 
contractions in rat aorta. Hypertension 22(4): 577-583. 
Nguyen NC, Taalab K, Osman MM (2010). Decreased blood flow with increased metabolic 
activity: a novel sign of pancreatic tumor aggressiveness. Clinical cancer research : an official 
journal of the American Association for Cancer Research 16(1): 367; author reply 567. 
 Novak I (2008). Purinergic receptors in the endocrine and exocrine pancreas. Purinergic Signal 
4(3): 237-253. 
Ralevic V, Burnstock G. (1998). Receptors for purines and pyrimidines. Pharmacological 
Reviews 50: 413-492. 
Rayment, SJ, Ralevic, V, Barrett, DA, Cordell, R, Alexander, SP (2007a) A novel mechanism 
of vasoregulation: ADP-induced relaxation of the porcine isolated coronary artery is mediated 
via adenosine release. FASEB J 21(2): 577-585. 
Rayment SJ, Latif ML, Ralevic V, Alexander SP (2007b). Evidence for the expression of 
multiple uracil nucleotide-stimulated P2 receptors coupled to smooth muscle contraction in 
porcine isolated arteries. Br J Pharmacol 150(5): 604-612. 
Roberts RE, Kendall DA, Wilson VG (1999). α2-Adrenoceptor and NPY receptor-mediated 
contractions of porcine isolated blood vessels: evidence for involvement of the vascular 
endothelium. Br J Pharmacol 128(8): 1705-1712. 
Robichaud J, Fournier JF, Gagne S, Gauthier JY, Hamel M, Han Y, et al. (2011). Applying the 
pro-drug approach to afford highly bioavailable antagonists of P2Y(14). Bioorganic & 
medicinal chemistry letters 21(14): 4366-4368. 
Satoh A, Shimosegawa T, Satoh K, Ito H, Kohno Y, Masamune A, et al. (2000). Activation of 
adenosine A1-receptor pathway induces edema formation in the pancreas of rats. 
Gastroenterology 119(3): 829-836. 
Scrivens M, Dickenson JM (2005). Functional expression of the P2Y14 receptor in murine T-
lymphocytes. Br J Pharmacol 146(3): 435-444. 
Scrivens M, Dickenson JM (2006). Functional expression of the P2Y14 receptor in human 
neutrophils. Eur J Pharmacol 543(1-3): 166-173. 
Sesma JI, Kreda SM, Steinckwich-Besancon N, Dang H, García-Mata R, Harden TK, et al. 
(2012). The UDP-sugar-sensing P2Y14 receptor promotes Rho-mediated signalling and 
chemotaxis in human neutrophils. American Journal of Physiology - Cell Physiology 303(5): 
C490-C498. 
Skelton L, Cooper M, Murphy M, Platt A (2003). Human immature monocyte-derived 
dendritic cells express the G protein-coupled receptor GPR105 (KIAA0001, P2Y14) and 
increase intracellular calcium in response to its agonist, uridine diphosphoglucose. J Immunol 
171(4): 1941-1949. 
Umapathy NS, Hick RT, Yu Y, Verin AD, (2010). Functional Expression of the Purinergic 
Receptor P2Y14 in the Human Lung Microvascular Endothelial Cells (HLMVEC). FASEB J. 
(Meeting Abstract Supplement) 111.9. 
Verin A, Zemskov E, Umapathy N, Lucas R (2011). P2Y receptors as regulators of lung 
endothelial barrier integrity. J Cardiovasc Dis Res 2(1): 14-22. 
von Kügelgen I (2006). Pharmacological profiles of cloned mammalian P2Y-receptor 
subtypes. Pharmacology &amp; Therapeutics 110(3): 415-432. 
Wihlborg AK, Wang L, Braun O, Eyjolfsson A, Ronny G, Gudbjartsson T, Erlinge D (2004). 
ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction 
in human blood vessels. Arterioscler Thromb Vasc Biol 24(10): 1810-1815. 
 Wong SL, Leung FP, Lau CW, Au CL, Yung LM, Yao X, et al. (2009). Cyclooxygenase-2-
derived prostaglandin F2alpha mediates endothelium-dependent contractions in the aortae of 
hamsters with increased impact during aging. Circ Res 104(2): 228-235. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure Legends 
 
Figure 1. (A) Concentration-dependent contractions evoked by UDP-glucose, UDP and 
MRS2690 in U46619-preconstricted porcine pancreatic arteries (**P < 0.01, two-way 
ANOVA, MRS2690 response vs UDP-glucose and UDP responses, F=13.74, 16.03; n=9-12). 
(B). Attenuation of UDP-glucose-induced contraction (the control) in the presence of UDP-
glucose (100 µM) and UDP (100 µM) (added 10 min prior to U46619 addition). Both UDP-
glucose and UDP significantly attenuated the contraction evoked by UDP-glucose (***P < 
0.001, two-way ANOVA, UDP-glucose contraction in the absence or presence of UDP-glucose 
or UDP, F=63.11, 56.48; n=10-13). Data are presented as mean ± SEM. 
 
Figure 2. Effect of PPADS (10 µM) and suramin (100 µM) on responses to (A) UDP-glucose, 
(B) UDP, and (C) MRS2690 in U46619-preconstricted porcine pancreatic arteries. (A) Suramin 
and PPADS enhanced the effects of UDP-glucose (***P < 0.001, two-way ANOVA, UDP-
glucose with suramin or PPADS vs UDP-glucose alone, F=19.85, 23.07; n=6-10). (B) Suramin 
and PPADS enhanced the effects of UDP (***P < 0.001, two-way ANOVA, UDP with suramin 
or PPADS vs UDP alone, F=16.83, 45.24; n=8-16). (C) Suramin and PPADS had no effect on 
the contraction to MRS2690 (n=5-9). Data are presented as mean ± SEM.  
 
 
 
 
 
 Figure 3. Effect of PPTN (1 µM), a P2Y14 receptor antagonist, on responses to (A) UDP-
glucose, (B) MRS2690, (C) UTP in U46619-preconstricted porcine pancreatic arteries. (A) 
PPTN inhibited the effect of UDP-glucose (*P < 0.05, two-way ANOVA, F=6.56; n=7). (B) 
PPTN inhibited the effect of MRS2690 (**P < 0.01, two-way ANOVA, F=12.85; n=9). (C) 
PPTN had no effect on the response to UTP (n=8-10). Data are presented as mean ± SEM. (D) 
Typical traces showing the effect of MRS2690 in the absence and in the presence of PPTN.  
 
Figure 4. Effect of removal of the endothelium on responses to (A) UDP-glucose, (B) UDP, 
(C) MRS2690, in U46619-preconstricted porcine pancreatic arteries. The removal of 
endothelium reduced the contractions evoked by (A) UDP-glucose, (B) UDP, (C) MRS2690 
(**P < 0.01, ***P < 0.001, two-way ANOVA, F=8.15, 51.24, 9.48; n=4-15). Data are 
presented as mean ± SEM. 
 
Figure 5. Effect of DUP 697 (3 µM) on responses to (A) UDP-glucose, (B) UDP, (C) 
MRS2690 in U46619-preconstricted porcine pancreatic arteries. DUP 697 inhibited the 
contractions evoked by (A) UDP-glucose, (B) UDP, (C) MRS2690 (** P < 0.01, *** P < 0.001, 
two-way ANOVA, F=7.85, 35.31, 4.95; n=4-15). Data are presented as mean ± SEM. 
 
 
 
 
 
 
 
 Figure 6. The contraction evoked by UDP-glucose in the presence of (A) NDGA (10 µM), (B) 
BQ123 (1 µM), (C) zafirlukast (10 µM) in U46619-preconstricted porcine pancreatic arteries, 
(D) L-655,240 (1 µM) in endothelin-1-preconstricted porcine pancreatic arteries. (A), (C) 
NDGA and zafirlukast did not alter the response to UDP-glucose (n=7-10). (B), (D) BQ-123 
and L-655,240 inhibited the response evoked by UDP-glucose (*P < 0.05, ***P < 0.001, two-
way ANOVA, F=4.97, 19.03;  n=9-14). Data are presented as mean ± SEM. 
 
Figure 7. Effect of (A) nifedipine (1 µM) and (B) thapsigargin (100 nM) on the response to 
UDP-glucose in U46619-preconstricted porcine pancreatic arteries. Both inhibitors, nifedipine 
and thapsigargin, inhibited the contraction evoked by UDP-glucose (*P < 0.05, ***P < 0.001, 
two-way ANOVA, F=32.5, 5.84; n= 9-13). Data are presented as mean ± SEM. (C) Typical 
traces showing the responses of UDP-glucose in the absence and in the presence of nifedipine.  
 
Figure 8. Effect of Y-27632 (5 µM), a selective inhibitor of the Rho-associated protein kinase 
on responses to (A) UDP, (B) MRS2690 in U46619-preconstricted porcine pancreatic arteries. 
Y-27632 reduced the contraction to (A) UDP, (B) MRS2690 (***P < 0.001, two-way ANOVA, 
F=53.07, 10.32; n=9-15). Data are presented as mean ± SEM. (C) MLC2 phosphorylation 
induced by 100 μM UDP-glucose in porcine pancreatic arteries. A  time-course (above) and a 
representative blot (below) of phospho- (green) and total- (red) MLC2 (*P < 0.05, one-way 
ANOVA, n=4).  
 
 
 Figure 9. PPTN, a selective high affinity antagonist of P2Y14 receptor, abolished the ability of 
UDP-glucose and MRS2690 to elevate the level of MLC phosphorylation (*P < 0.05, Student’s 
unpaired t-test, n=3). Data are presented as mean ± SEM. Representative immunoblots of 
phospho- (green) and total- (red) MLC2 from three separate experiments in the absence or 
presence of PPTN.  
 
Figure 10. Effect of preconstriction with U46619 followed by relaxation with forskolin (1 µM) 
on the responses to (A) UDP-glucose, (B) UTP in porcine pancreatic arteries. (A) Exposing the 
tissues to U46619 followed by forskolin significantly enhanced the contraction evoked by 
UDP-glucose (***P < 0.001, two-way ANOVA, F=54.34; n=8-13). Data are presented as mean 
± SEM. (B) Exposing the tissues to U66619 followed by forskolin failed to affect the response 
to UTP. (C) Typical traces showing the effect of UDP-glucose on basal tone (inset) and after 
the tissues were preconstricted with U46619 and then relaxed with forskolin (main). 
  
 
Figure 11. Effect of UTP (1 mM), UDP-glucose 1 (mM) and MRS2690 (10 µM) on the cAMP 
concentrations in porcine pancreatic arteries exposed to U46619 followed by forskolin. UTP 
had no significant effect on cAMP level, while UDP-glucose and MRS2690 reduced 
significantly the cAMP level (*P < 0.05, Student’s unpaired t-test, the response to UTP or 
UDP-glucose or MRS2690 vs their respective controls, n=4). Basal cyclic AMP level 
represents the level of cAMP in the absence of forskolin which was also significantly different 
to that in the presence of forskolin (*P < 0.05, Student’s unpaired t-test, n=4). Data are 
presented as mean ± SEM. 
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